EAU 2021 | Metastasis-directed therapy for oligorecurrent prostate cancer
Piet Ost, MD, PhD, Ghent University, Ghent, Belgium, discusses the findings of a meta-analysis of data from four trials investigating the safety and clinical benefit of metastasis-directed therapy for oligorecurrent prostate cancer. Data from 174 patients, 72% of whom received metastasis-directed therapy and 28% of whom were kept under active surveillance, was analyzed. The study reported that metastasis-directed therapy improved both biochemical-free and androgen deprivation therapy-free survival in comparison with active surveillance. This interview took place at the virtual European Association of Urology (EAU) Virtual Meeting 2021.
Disclosures
Piet Ost, MD, PhD, has received institutional grants or research support from Merck, Bayer, Ferring and Varian; and has received honoraria or consultation fees from Astellas, Bayer, Ferring, Janssen, Sanofi and Sandoz.
